[go: up one dir, main page]

NO983669D0 - Coralyne analoger som topoisomeraseinhibitorer - Google Patents

Coralyne analoger som topoisomeraseinhibitorer

Info

Publication number
NO983669D0
NO983669D0 NO983669A NO983669A NO983669D0 NO 983669 D0 NO983669 D0 NO 983669D0 NO 983669 A NO983669 A NO 983669A NO 983669 A NO983669 A NO 983669A NO 983669 D0 NO983669 D0 NO 983669D0
Authority
NO
Norway
Prior art keywords
coralyne
analogues
topoisomerase inhibitors
topoisomerase
inhibitors
Prior art date
Application number
NO983669A
Other languages
English (en)
Other versions
NO983669L (no
Inventor
Edmond J Lavoie
Leroy Fong Liu
Darshan B Makhey
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Publication of NO983669D0 publication Critical patent/NO983669D0/no
Publication of NO983669L publication Critical patent/NO983669L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO983669A 1996-02-12 1998-08-11 Coralyne analoger som topoisomeraseinhibitorer NO983669L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1145296P 1996-02-12 1996-02-12
US3216196P 1996-10-01 1996-10-01
PCT/US1997/001676 WO1997029106A1 (en) 1996-02-12 1997-02-11 Coralyne analogs as topoisomerase inhibitors

Publications (2)

Publication Number Publication Date
NO983669D0 true NO983669D0 (no) 1998-08-11
NO983669L NO983669L (no) 1998-09-23

Family

ID=26682407

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983669A NO983669L (no) 1996-02-12 1998-08-11 Coralyne analoger som topoisomeraseinhibitorer

Country Status (18)

Country Link
EP (1) EP0888346B1 (no)
JP (1) JP2000504687A (no)
KR (1) KR19990082488A (no)
CN (1) CN1067070C (no)
AU (1) AU710070C (no)
BR (1) BR9707425A (no)
CA (1) CA2241551A1 (no)
CZ (1) CZ254498A3 (no)
DE (1) DE69705112T2 (no)
ES (1) ES2161442T3 (no)
HU (1) HUP9900413A3 (no)
IL (1) IL124803A0 (no)
NO (1) NO983669L (no)
NZ (1) NZ330705A (no)
PL (1) PL328402A1 (no)
PT (1) PT888346E (no)
TR (1) TR199801555T2 (no)
WO (1) WO1997029106A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW460464B (en) * 1996-11-25 2001-10-21 Nippon Kayaku Kk Novel phenanthridinium derivative having an anti-tumor activity and pharmaceutical composition containing the same
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
US6063801A (en) * 1998-02-12 2000-05-16 Rutgers, The State University Of New Jersey Heterocyclic topoisomerase poisons
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CN1093129C (zh) * 1999-08-19 2002-10-23 广州市海科生物技术有限公司 一种具有抗肿瘤生理活性的尖叶唐松草阿原碱及其提取方法
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
PT1465625E (pt) 2001-11-14 2010-03-09 Univ Rutgers Venenos de topoisomerase solubilizados
MXPA04004607A (es) 2001-11-14 2004-09-10 Univ Rutgers Agentes de venenos de topoisomerasa solubilizados.
AU2002364953A1 (en) 2001-11-14 2003-06-17 Edmond J. Lavoie Topoisomerase poison agents
AU2003268075A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
WO2004014918A1 (en) 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
JP4774212B2 (ja) 2002-11-12 2011-09-14 ラトガーズ、ザ・ステイト・ユニバーシテイ・オブ・ニユー・ジヤージー トポイソメラーゼ−ターゲッティング剤
AU2006275514B2 (en) 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
KR101444489B1 (ko) 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
WO2010102219A1 (en) 2009-03-06 2010-09-10 Rutgers, The State University Of New Jersey Methylenedioxybenzo [i] phenanthridine derivatives used to treat cancer
KR101841003B1 (ko) 2009-03-18 2018-03-22 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
US8188109B2 (en) * 2009-07-20 2012-05-29 Naxospharma S.R.L. Benzoquinolizinium salt derivatives as anticancer agents
CN102746292B (zh) * 2011-04-18 2015-03-18 中国医学科学院医药生物技术研究所 环化的小檗碱衍生物及其制备方法和用途
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2014144097A1 (en) * 2013-03-15 2014-09-18 Georgetown University Antifungal drugs
NZ718190A (en) 2013-08-23 2017-10-27 Neupharma Inc Substituted quinazolines for inhibiting kinase activity
AU2016220219B2 (en) * 2015-02-17 2020-05-14 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN107530356A (zh) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
CN105541714A (zh) * 2015-12-16 2016-05-04 浙江普洛康裕制药有限公司 一种罂粟碱及盐酸罂粟碱的制备方法
WO2017176648A1 (en) 2016-04-04 2017-10-12 Rutgers, The State University Of New Jersey Topoisomerase poisons
AU2017312561B2 (en) 2016-08-15 2022-06-30 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN110759963A (zh) * 2018-07-25 2020-02-07 中山大学 一种稠环类化合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126351A (en) * 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
US5223506A (en) * 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds

Also Published As

Publication number Publication date
BR9707425A (pt) 1999-07-20
HUP9900413A3 (en) 2002-02-28
EP0888346B1 (en) 2001-06-06
NO983669L (no) 1998-09-23
WO1997029106A1 (en) 1997-08-14
CZ254498A3 (cs) 1998-12-16
PT888346E (pt) 2001-10-31
DE69705112D1 (en) 2001-07-12
CN1067070C (zh) 2001-06-13
AU2115597A (en) 1997-08-28
EP0888346A1 (en) 1999-01-07
HUP9900413A2 (hu) 1999-05-28
DE69705112T2 (de) 2002-03-21
IL124803A0 (en) 1999-01-26
TR199801555T2 (xx) 1998-11-23
ES2161442T3 (es) 2001-12-01
CN1211252A (zh) 1999-03-17
NZ330705A (en) 2000-03-27
KR19990082488A (ko) 1999-11-25
AU710070B2 (en) 1999-09-16
AU710070C (en) 2001-08-30
CA2241551A1 (en) 1997-08-14
PL328402A1 (en) 1999-01-18
JP2000504687A (ja) 2000-04-18

Similar Documents

Publication Publication Date Title
NO983669D0 (no) Coralyne analoger som topoisomeraseinhibitorer
NO992725D0 (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
NO992821D0 (no) Ketobenzamider som calpain-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1124779T3 (da) D-vitaminanaloge forbindelser
NO980467L (no) 4-mercaptopyrrolidin-derivater som farnesyl-transerase-inhibitorer
DK1086101T3 (da) Beta-carbolinforbindelser
IS7292A (is) Staðgengnar bensensúlfonamíðafleiður sem forlyf fyrir COX-2 tálma
DK0888359T3 (da) Pyrimidin-4-on-derivat som pesticid
NO985874D0 (no) Bestemte fosfinylderivater nyttige som naaladase inhibitorer
DK0808833T3 (da) D3-vitamin-analoger
DK1235777T3 (da) Vitamin D-analoger
NO991384D0 (no) Substituerte heterocykler som anti-tumormidler
ATE272062T1 (de) Spirocyclisch metalloprotease inhibitoren
DK0915819T3 (da) Illudinanaloger anvendt som antitumormiddel
DK0922034T3 (da) Tetrahydroquinolinderivater som EAA-antagonister
NO991560D0 (no) PDE IV som inhiberer 2-cyanoiminoimidazol-derivater
NO982651D0 (no) 3-Azetidinylalkylpiperidiner eller -pyrrolidiner som takykininantagonister
NO20001924L (no) Isoquinoliner som urokinase-inhibitorer
DK1007512T3 (da) Forgrenede alkoxysubstituerede 2-aminopyridiner som NOS-inhibitorer
DK1235824T3 (da) D-vitaminanaloge forbindelser
DK0747346T3 (da) N-acyl-2-arylcyclopropylmethylaminderivater som melatonerge midler
NO20000434D0 (no) Lyksofuranosyl benzimidazoler som antivirale midler
FI963725A0 (fi) Bastuugn som vaermar vatten
FI961508A0 (fi) Ledningskanal som ocksao fungerar som foensterbraede

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application